Tango Therapeutics Inc at Guggenheim Healthcare Talks Oncology Day Transcript
I'm Charles Zhu and a senior biotech analyst here at Guggenheim Securities. For our next session, we have Tango Therapeutics here for next fireside. With us here today is Barbara from Tango. Thanks for your participation and for joining us.
Questions & Answers
Perhaps just to kick us off, could you provide an overview of your company platform and pipeline?
Yeah, sure. Thanks. And thanks for the invitation. So, Tango Therapeutics is a company that we started back in 2017, supported by Third Rock Ventures with the idea behind it that a lot of progress had been made in targeting activated oncogenes in cancer over the last 10 or 15 years. But with that all those cancers also have to suppressor gene loss. And that there was no other way actually other than synthetic lethality, really on a large-scale effort to get at those potential targets.
So, Tango was
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
